Mammakarzinom: Neuerungen in Früherkennung und Diagnostik

Durch neue Erkenntnisse in der bildgebenden und histologisch-genetischen Diagnostik und Früherkennung des Mammakarzinoms können Untersuchungen risikoadaptierter und Behandlungen tumorspezifischer durchgeführt werden. Hierdurch sollen Brustkrebserkrankungen in früheren Stadien erkannt, die Mortalität gesenkt und gleichzeitig eine Übertherapie vermieden werden.

Schlüsselwörter

Mammakarzinom - Früherkennung - Screening - Diagnostik - Bildgebung

• Literatur

• 1 RKI. Bericht zum Krebsgeschehen in Deutschland (2016). Im Internet: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_download.pdf?__blob=publicationFile Stand: 04.01.2019
• 2 S3-Leitlinie Diagnostik, Therapie und Nachsorge des Mammakarzinoms (Version 4.0, 2017). Im Internet: https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ Stand: 04.01.2019
• 3 Duke Evidence Synthesis Group, Guidelines Development Group. Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines. Durham, NC: Duke Clinical Research Institute; 2014
• 4 World Health Organization. WHO Position Paper on Mammography Screening. Geneva: World Health Organization; 2014
• 5 Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012; 367: 1998-2005
• 6 Helvie MA, Chang JT, Hendrick RE. et al. Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer. Cancer 2014; 120: 26492656
• 7 Mammografie Screening-Programm, Publikationen und Stellungnahmen. Im Internet: https://fachservice.mammo-programm.de/publikationen-und-stellungnahmen Stand: 04.01.2019
• 8 Kuchenbaecker KB, Hopper JL, Barnes DR. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317: 2402-2416 doi:10.1001/jama.2017.7112
• 9 Schulz-Wendtland R, Bani M, Lux MP. et al. Pilot study on the detection of simulated lesions using a 2D and 3D digital full-field mammography system with a newly developed high resolution detector based on two shifts of a-Se. Geburtshilfe Frauenheilkd 2012; 72: 408-411
• 10 Broeders M, Moss S, Nyström L. et al. EUROSCREEN Working Group. The impact of mammografic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 2012; 19 (Suppl. 01) 14-25
• 11 Schulz-Wendtland R, Dilbat G, Bani M. et al. Full field digital mammography (FFDM) versus CMOS technology, specimen radiography system (SRS) and tomosynthesis (DBT) – which system can optimise surgical therapy?. Geburtshilfe Frauenheilkd 2013; 73: 422-427
• 12 Hodgson R, Heywang-Köbrunnerb S, Harvey S. et al. Systematic review of 3D mammography for breast cancer screening. Breast 2016; 27: 52-61
• 13 Bennani-Baiti B, Bennani-Baiti N, Baltzer PA. Diagnostic performance of breast magnetic resonance imaging in non-calcified equivocal breast findings: Results from a systematic review and meta-analysis. PLoS One 2016; 11: e0160346 doi:10.1371/journal.pone.0160346
• 14 Perry N, Broeders M, de Wolf C. et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition–summary document. Ann Oncol 2008; 19: 614-622
• 15 AGO Guidelines Breast Version 2018.1D. Im Internet: https://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2018-03/Gesamt_deutsch/Alle_aktuellen_Empfehlungen_2018.pdf Stand 04.01.2019
• 16 Coates AS, Winer EP, Goldhirsch A. et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533-1546
• 17 Deyarmin B, Kane JL, Valente AL. et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Ann Surg Oncol 2013; 20: 87-93
• 18 Iwamoto T, Booser D, Valero V. et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012; 30: 729-734
• 19 Prabhu JS, Korlimarla A, Desai K. et al. A majority of low (1-10%) ER positive breast cancers behave like hormone receptor negative tumors. J Cancer 2014; 5: 156-165
• 20 Sanford RA, Song J, Gutierrez-Barrera AM. et al. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer 2015; 121: 3422-3427
• 21 Yi M, Huo L, Koenig KB. et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 2014; 25: 1004-1011
• 22 Couch FJ, Shimelis H, Hu C. et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 2017; 3: 1190-1196 doi:10.1001/jamaoncol.2017.0424